Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Qilian International Holding Group Limited (BGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/24/2025: BGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -73.69% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/24/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.48B USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 1.46 | 52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 |
52 Weeks Range 3.33 - 17.17 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.2 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -26.32% | Operating Margin (TTM) -5.41% |
Management Effectiveness
Return on Assets (TTM) -3.84% | Return on Equity (TTM) -16.52% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 |
Enterprise Value 2465318227 | Price to Sales(TTM) 83.14 | ||
Enterprise Value to Revenue 98.23 | Enterprise Value to EBITDA 2801.9 | Shares Outstanding 163960000 | Shares Floating 2832616 |
Shares Outstanding 163960000 | Shares Floating 2832616 | ||
Percent Insiders 7.29 | Percent Institutions - |
Upturn AI SWOT
Qilian International Holding Group Limited
Company Overview
History and Background
Qilian International Holding Group Limited (QLI) focuses on the research, development, manufacture, and marketing of traditional Chinese medicine products, nutritional products, and bio-therapeutic products. Information regarding founding year and detailed milestones are limited in readily available public sources.
Core Business Areas
- Traditional Chinese Medicine Products: Development and sales of various TCM products.
- Nutritional Products: Manufacture and distribution of nutritional supplements and health foods.
- Bio-therapeutic Products: Research and production of bio-therapeutic medications.
Leadership and Structure
Information regarding the current specific leadership team and detailed organizational structure is limited in readily available public sources.
Top Products and Market Share
Key Offerings
- Traditional Chinese Medicine Products: Various TCM formulations targeting specific health conditions. Specific market share data is unavailable. Competitors include other TCM manufacturers.
- Nutritional Supplements: Dietary supplements and health foods aimed at general wellness. Specific market share data is unavailable. Competitors include supplement brands like GNC and Nature Made.
- Bio-therapeutic Products: Specific bio-therapeutic products are difficult to ascertain without access to non-public information. Specific market share data is unavailable. Competitors include established pharmaceutical companies.
Market Dynamics
Industry Overview
The traditional Chinese medicine and nutraceuticals markets are growing, driven by increased interest in alternative and preventative healthcare. The bio-therapeutics market is expanding due to advancements in biotechnology.
Positioning
Qilian International Holding Group Limited is positioned as a player in the Chinese medicine and health supplement market. Without specific market share data, its competitive advantages are difficult to definitively determine.
Total Addressable Market (TAM)
The global TCM market is substantial, with estimates reaching billions of dollars. Qilian International's positioning relative to this TAM is difficult to assess without precise revenue and market share figures.
Upturn SWOT Analysis
Strengths
- Established presence in the Chinese market
- Focus on traditional medicine and health products
- Diversified product portfolio
- Potential for growth in the expanding health and wellness market
Weaknesses
- Limited brand recognition outside of China
- Lack of detailed financial information and market share data
- Dependency on the Chinese regulatory environment
- Relatively small size compared to major pharmaceutical companies
Opportunities
- Expansion into international markets
- Increased demand for natural and alternative therapies
- Strategic partnerships and acquisitions
- Development of innovative products
Threats
- Intense competition from larger pharmaceutical and nutraceutical companies
- Changes in regulations affecting the TCM and health product industries
- Economic slowdown in China
- Negative publicity or product recalls
Competitors and Market Share
Key Competitors
- Insufficient data to provide meaningful comparables
Competitive Landscape
The competitive landscape is difficult to assess without identifying key competitors and their respective market shares.
Growth Trajectory and Initiatives
Historical Growth: Historical growth trends are difficult to assess without access to past financial statements.
Future Projections: Future growth projections cannot be accurately made without current financial data and analyst coverage.
Recent Initiatives: Recent strategic initiatives are difficult to ascertain without access to company announcements or public filings.
Summary
Qilian International Holding Group Limited, operating in the TCM and health supplement markets, faces challenges due to limited financial transparency and market data. Growth prospects are uncertain without sufficient information to analyze its competitive position and strategic initiatives. The lack of recent public financial data makes it difficult to assess the company's current strength and potential risks. Investors should exercise caution due to the limited available information.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC filings (limited availability)
- Company website (limited information)
- Various financial news sources
Disclaimers:
The information provided is based on limited publicly available data and may not be entirely accurate or complete. This analysis is for informational purposes only and does not constitute investment advice. Due to delisting, the current stock performance and financial outlook have significant uncertainty.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Qilian International Holding Group Limited
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2024-08-12 | CEO - | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 298 | Website https://www.bgm.ltd |
Full time employees 298 | Website https://www.bgm.ltd | ||
BGM Group Ltd manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. The company was formerly known as Qilian International Holding Group Limited and changed its name to BGM Group Ltd in October 2024. BGM Group Ltd was incorporated in 2019 and is based in Chengdu, the People's Republic of China.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.